enGene (NASDAQ:ENGN – Get Free Report) and SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends and analyst recommendations.
Volatility and Risk
enGene has a beta of -0.65, suggesting that its stock price is 165% less volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.
Institutional & Insider Ownership
64.2% of enGene shares are held by institutional investors. 13.7% of enGene shares are held by insiders. Comparatively, 7.6% of SpringWorks Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| enGene | N/A | N/A | -$99.92 million | ($0.58) | -13.12 |
| SpringWorks Therapeutics | $135.49 million | 23.61 | -$325.10 million | ($3.88) | -11.08 |
enGene has higher earnings, but lower revenue than SpringWorks Therapeutics. enGene is trading at a lower price-to-earnings ratio than SpringWorks Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares enGene and SpringWorks Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| enGene | N/A | -66.38% | -56.00% |
| SpringWorks Therapeutics | -203.09% | -48.21% | -42.19% |
Analyst Ratings
This is a breakdown of recent ratings and price targets for enGene and SpringWorks Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| enGene | 0 | 0 | 10 | 1 | 3.09 |
| SpringWorks Therapeutics | 0 | 0 | 6 | 0 | 3.00 |
enGene currently has a consensus target price of $29.78, indicating a potential upside of 291.30%. SpringWorks Therapeutics has a consensus target price of $70.00, indicating a potential upside of 62.79%. Given enGene’s stronger consensus rating and higher probable upside, research analysts clearly believe enGene is more favorable than SpringWorks Therapeutics.
Summary
enGene beats SpringWorks Therapeutics on 9 of the 14 factors compared between the two stocks.
About enGene
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
About SpringWorks Therapeutics
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
